Tuesday, July 20, 2021 5:48:01 PM
theswordman - you don't disagree. You don't understand or perhaps are not aware of the circumstances around ECOR and why it was and is an absolute horror show of an investment. This factually sits on Errico and the rest of the founding and leadership team.
Financials:
Company way way overpriced with last two rounds of investment converting at around $10+ per share
IPO price offered to the investors at around $15 per share
The stock spent about a few hours above the offering price and immediately started to sink
All early (pre IPO investors were locked/restricted in share transaction activity for about 1 year (could be off but not by much)
At the time restriction was lifted the shares were worth less than 20% of the original investment
Here's the kicker - when selling the investment opportunity to investors, the sales projections were listed as $42MM for 2018, $142MM for 2019 and $280MM for 2020. You can do your own research but I can tell you that they are just getting to $12MM +/- in sales for 2021.... Yes - it was supposed to be $280MM last year and the numbers are just creeping past $12M. Brilliant.
So yes - nothing about this investment or the people associated with it is anything to highlight as a success or a target of association. At ANY level and any aspect of the business throughout its lifecycle to the present.
MOA and Therapeutic Modality
One more very important note.
To compare the development, testing and regulatory approval of a non invasive medical device designed to address pain management (no disrespect to pain or migraines which are devastating to have) to the process of developing testing and approving a biologic that targets viral entry and immune response/modulation on the cutting edge of science and current knowledge is absurd and a non starter.
The ECOR device, though innovative, is an external version of an implantable product whereby the science behind contact based vagus nerve stimulation was well understood over a very long period. While developing an innovative way to transmit elect stimulation impulses through the skin required some creativity and engineering prowess, it is just that and incomparable to the work going on to develop CCR5 based therapeutics.
There's so much more to say about the subject as well as the magnificent 13 but that is not the topic. Let's just not confuse ElectroCore with anything positive and at any level.
Financials:
Company way way overpriced with last two rounds of investment converting at around $10+ per share
IPO price offered to the investors at around $15 per share
The stock spent about a few hours above the offering price and immediately started to sink
All early (pre IPO investors were locked/restricted in share transaction activity for about 1 year (could be off but not by much)
At the time restriction was lifted the shares were worth less than 20% of the original investment
Here's the kicker - when selling the investment opportunity to investors, the sales projections were listed as $42MM for 2018, $142MM for 2019 and $280MM for 2020. You can do your own research but I can tell you that they are just getting to $12MM +/- in sales for 2021.... Yes - it was supposed to be $280MM last year and the numbers are just creeping past $12M. Brilliant.
So yes - nothing about this investment or the people associated with it is anything to highlight as a success or a target of association. At ANY level and any aspect of the business throughout its lifecycle to the present.
MOA and Therapeutic Modality
One more very important note.
To compare the development, testing and regulatory approval of a non invasive medical device designed to address pain management (no disrespect to pain or migraines which are devastating to have) to the process of developing testing and approving a biologic that targets viral entry and immune response/modulation on the cutting edge of science and current knowledge is absurd and a non starter.
The ECOR device, though innovative, is an external version of an implantable product whereby the science behind contact based vagus nerve stimulation was well understood over a very long period. While developing an innovative way to transmit elect stimulation impulses through the skin required some creativity and engineering prowess, it is just that and incomparable to the work going on to develop CCR5 based therapeutics.
There's so much more to say about the subject as well as the magnificent 13 but that is not the topic. Let's just not confuse ElectroCore with anything positive and at any level.
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
